1533 Monrovia Avenue
98 articles with Biomerica Inc.
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
Biomerica Inc. today announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica’s new and proprietary Helicobacter pylori test, called hp+detect™.
Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
Biomerica, Inc. (NASDAQ: BMRA) today announced that the Mexican Patent Office has issued a notice of allowance for Biomerica’s patent application pertaining to the Company’s InFoods® technology platform that offers a revolutionary approach in the treatment of patients suffering from Irritable Bowel Syndrome (“IBS”).
Biomerica, Inc., a global provider of advanced medical products, announced that it will be participating in two upcoming investor conferences: the Truist Life Sciences Series and LD Micro Invitational XI event.
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, announced that its new COVID-19 Antigen Rapid Test can now be performed with a simple less invasive nasal swab
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced its fiscal third quarter 2021 financial results for the three months ended February 28, 2021.
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced financial results for its second quarter of fiscal year 2021, which ended November 30, 2020.
Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment
Patient enrollment completion anticipated by the end of April 2021 InFoods® Diagnostic-Guided Therapy is designed to address the $30 billion market for IBS treatment Therapy seeks to identify patient-specific foods that trigger IBS symptoms and suffering Approximately 45 million Americans suffer from IBS 1
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August 31, 2020. Net sales for the three months ended August 31, 2020 were $1.14 million compared to net sales of $1.19 million for the same period of 2019. Net loss was $1.6 million for the three months ended August 31, 2020 compared to a net loss of $0.5 million for the same period in the previous yea
9/4/2020Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Fiscal fourth quarter revenues increase 133.7% over the prior year Fiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods ® patent granted for Singapore
Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors
Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years of dedicated service, Ms. Moore has decided to retire and pursue personal interests
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests
Biomerica Inc. (NASDAQ: BMRA ) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s second U.S. patent pertaining to the Company’s InFoods® technology platform that offers a revolutionary new way to treat patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application #16/385,322 contains numerous claims that broadl
Biomerica Inc. announced that it has filed a new three year shelf registration statement on Form S-3 with the United States Securities and Exchange Commission to replace its previous three year shelf registration statement, which was declared effective by the SEC in July 2017.
The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial
Biomerica Inc. (NASDAQ: BMRA) today announced it has signed a definitive agreement with the University of Texas Health Science Center at Houston (“UTH”) to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.
Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19
This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. This test adds to the previously announced Biomerica 10-minute finger prick antibody tests already being sold outside of the US Biomerica has filed a provisional patent on technology to allow simplified blood collection
Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial
Biomerica also announces its first Japanese patent has been granted for its InFoods® IBS Diagnostic Guided Therapy technology
Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution
New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office utilizing blood from a finger prick.
Biomerica, Inc. reported net sales of $3,967,712 for the nine months ending February 29, 2020, compared to $4,034,822 for the period ended February 28, 2019.
Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs
Biomerica Inc. (NASDAQ: BMRA ) today announced it has signed two separate definitive license agreements with Mount Sinai’s Icahn School of Medicine in New York
10-minute test for coronavirus exposure utilizing blood from a finger prick can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office